281 related articles for article (PubMed ID: 35008981)
1. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.
Wang X; Kaiser H; Kvist-Hansen A; McCauley BD; Skov L; Hansen PR; Becker C
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008981
[TBL] [Abstract][Full Text] [Related]
2. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
3. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
4. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.
Cao H; Su S; Yang Q; Le Y; Chen L; Hu M; Guo X; Zheng J; Li X; Yu Y
Lipids Health Dis; 2021 Feb; 20(1):16. PubMed ID: 33602246
[TBL] [Abstract][Full Text] [Related]
5. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis.
Fang H; Hou Y; Zhuang H; Wang C
New Microbiol; 2022 Apr; 45(2):130-137. PubMed ID: 35699562
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Serum Proinflammatory Cytokine IL-17A and Tight Junction Protein Claudin-1 in Psoriasis.
Xu L; Pan Y; Tang S; Bai J; Wu Y; Qiao J; Fang H
Contrast Media Mol Imaging; 2022; 2022():6092808. PubMed ID: 35340911
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
Yu Q; Tong Y; Cui L; Zhang L; Gong Y; Diao H; Gao F; Shi Y
Int Immunopharmacol; 2019 Aug; 73():442-450. PubMed ID: 31154289
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis.
Wang Y; Zang J; Liu C; Yan Z; Shi D
Front Immunol; 2022; 13():835671. PubMed ID: 35514987
[TBL] [Abstract][Full Text] [Related]
9. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-17A suppresses granular layer formation in a 3-D human epidermis model through regulation of terminal differentiation genes.
Sato E; Yano N; Fujita Y; Imafuku S
J Dermatol; 2020 Apr; 47(4):390-396. PubMed ID: 32020672
[TBL] [Abstract][Full Text] [Related]
11. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
12. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
von Stebut E; Boehncke WH; Ghoreschi K; Gori T; Kaya Z; Thaci D; Schäffler A
Front Immunol; 2019; 10():3096. PubMed ID: 32010143
[TBL] [Abstract][Full Text] [Related]
13. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model.
Al-Harbi NO; Nadeem A; Al-Harbi MM; Zoheir KMA; Ansari MA; El-Sherbeeny AM; Alanazi KM; Alotaibi MR; Ahmad SF
Immunobiology; 2017 Feb; 222(2):128-136. PubMed ID: 27773660
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
17. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
Johnston A; Fritz Y; Dawes SM; Diaconu D; Al-Attar PM; Guzman AM; Chen CS; Fu W; Gudjonsson JE; McCormick TS; Ward NL
J Immunol; 2013 Mar; 190(5):2252-62. PubMed ID: 23359500
[TBL] [Abstract][Full Text] [Related]
18. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
[TBL] [Abstract][Full Text] [Related]
19. Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly.
Mylle S; Grine L; Speeckaert R; Lambert JLW; van Geel N
Am J Clin Dermatol; 2018 Oct; 19(5):625-637. PubMed ID: 30003497
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation.
Xu X; Prens E; Florencia E; Leenen P; Boon L; Asmawidjaja P; Mus AM; Lubberts E
Front Immunol; 2021; 12():719562. PubMed ID: 34616394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
